Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Open access

Abstract

Predicting tumor sensitivity to antineoplastics remains an elusive challenge, with no methods demonstrating predictive power. Joint analysis of tumors—from patients with distinct malignancies who had progressed on multiple lines of therapy—and drug perturbation transcriptional profiles predicted sensitivity to 28 of 350 drugs, 26 of which (93%) were confirmed in low-passage, patient-derived xenograft (PDX) models. Drugs were prioritized based on their ability to either invert the activity of individual Master Regulator proteins, with available high-affinity inhibitors, or of the modules they comprise (Tumor-Checkpoints), based on de novo mechanism of action analysis. Of 138 PDX mice enrolled in 16 single and 18 multi-protein treatment arms, a disease control rate (DCR) of 68% and 91 %, and an objective response rate (ORR) of 12% and 17%, were achieved respectively, compared to 6% and 0% in the negative controls arm, with multi-protein drugs achieving significantly more durable responses. Thus, these approaches may effectively complement and expand current precision oncology approaches, as also illustrated by a case study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.10.03.462951

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Cited by

See all 51

Metadata

Authors
Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., Karan, C., Ortiz, M. V., Accordino, M., Mistretta, S., Brogan, F., Bruce, J. N., Caescu, C. I., Carvajal, R., Crew, K., Decastro, G., Heaney, M., Henick, B., Hershman, D., Hou, J., Iwamoto, F., Jurcic, J., Kiran, R. P., Kluger, M., Kreisl, T., Lamanna, N., Lassman, A., Lim, E., Manji, G. A., McKhann, G., McKiernan, J., Neugut, A., Olive, K., Rosenblat, T., Schwartz, G. K., Shu, C., Sisti, M., Tergas, A., Vattakalam, R., Welch, M., Wenske, S., Wright, J. D., Hibshoosh, H., Kalinsky, K., Aburi, M., Sims, P. A., Alvarez, M. J., Kung, A. L., & Califano, A.
Affiliations
  • Columbia University Irving Medical Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Emory University (US)
Corresponding author
  • Alvarez, Mariano J.
  • Kung, Andrew L.
  • Califano, Andrea
Venue
Cancer Discovery
Publisher
openRxiv
Published
2021-10-03
Volume
13
Issue
6
Pages
1386-1407
ISSN
2159-8274 (ISSN-L)
OpenAlex
W4365997950
Cited by
51
References
85
Citations by year
2026: 15 · 2025: 14 · 2024: 7 · 2023: 10 · 2022: 5
FWCI
6.58
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • CureSearch for Children's Cancer
  • Memorial Sloan-Kettering Cancer Center (CA008748, P30 CA008748)
  • National Institutes of Health (1s10od021764-01, 1s10od032433-01a1, 1s10od012351-01, CA008748, CA013696)
  • Irving Medical Center, Columbia University (P30 CA008748)
  • NIH Office of the Director (S10OD021764, S10 OD012351)
  • National Cancer Institute (S10OD021764, S10 OD012351, U54CA209997, CA008748, CA013696, OD012351, CA209997, U01CA217858, CA217858, OD021764, P30CA008748, U01CA272610, R35CA197745, P30CA013696)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
precision oncology, patient-derived xenografts, oncotarget, drug response prediction, basket trials, umbrella trials, disease control rate
MeSH terms
Antineoplastic Agents, Humans, Medical Oncology, Neoplasms, Precision Medicine, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments. https://app.cochat.ai/papers/10.1101/2021.10.03.462951
The paper
Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., Karan, C., Ortiz, M. V., Accordino, M., Mistretta, S., Brogan, F., Bruce, J. N., Caescu, C. I., Carvajal, R., Crew, K., . . . Califano, A. (2021). Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments. Cancer Discovery. https://doi.org/10.1101/2021.10.03.462951

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.